Role of Th1 and Th2 cytokines in BCG-induced IFN-γ production: Cytokine promotion and simulation of BCG effect

Cytokine

Volumn 21, Issue 1, 2003, Pages 17-26

  Luo, Yi ^a   Chen, Xiaohong ^a   O'Donnell, Michael A ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

BCG; Cytokine; Interferon ; Synergy; T helper type 1

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; TH1 CYTOKINE; TH2 CYTOKINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; CELL CULTURE; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INHIBITION KINETICS; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIMULATION; UPREGULATION;

MYCOBACTERIUM BOVIS BCG;

EID: 0037422679     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-4666(02)00490-8     Document Type: Article

References (46)

1. Alexandroff A.B., Jackson A.M., O'Donnell M.A., James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet. 353:1999;1689-1694.
2. O'Donnell M.A., DeWolf W.C. Bacillus Calmette-Guérin immunotherapy for superficial bladder cancer: new prospects for an old warhorse. Surg Oncol Clin North Am. 4:1995;189-202.
3. O'Donnell M.A. Use of intravesical BCG in treatment of superficial bladder cancer. Droller M.J. Bladder cancer: current diagnosis and treatment. 2001;225-265 Human Press, Totowa, NJ.
4. Bohle A., Nowc C., Ulmer A.J., Musehold J., Gerdes J., Hofstetter A.G., et al. Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guérin immunotherapy. J Urol. 144:1990;59-64.
5. de Reijke T.M., de Boer E.C., Kurth K.H., Schamhart D.H. Urinary cytokines during intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer: processing, stability and prognostic value. see comments J Urol. 155:1996;477-482.
6. Esuvaranathan K., Alexandroff A.B., McIntyre M., Jackson A.M., Prescott S., Chisholm G.D., et al. Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy. J Urol. 154:1995;572-575.
7. Prescott S., James K., Hargreave T.B., Chisholm G.D., Smyth J.F. Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. see comments J Urol. 144:1990;1248-1251.
8. Thalmann G.N., Sermier A., Rentsch C., Mohrle K., Cecchini M.G., Studer U.E. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guérin. J Urol. 164:2000;2129-2133.
9. Alexandroff A.B., Jackson A.M., Skibinska A., James K. Production of IL-5, a classical TH2 cytokine, following bacillus Calmette-Guérin immunotherapy of bladder cancer. Int J Oncol. 9:1996;179-182.
10. Huygen K., Abramowicz D., Vandenbussche P., Jacobs F., De Bruyn J., Kentos A., et al. Spleen cell cytokine secretion in Mycobacterium bovis BCG-infected mice. Infect Immun. 60:1992;2880-2886.
11. Pavlovich C.P., Kraling B.M., Stewart R.J., Chen X., Bochner B.H., Luster A.D., et al. BCG-induced urinary cytokines inhibit microvascular endothelial cell proliferation. J Urol. 163:2000;2014-2021.
12. Poppas D.P., Pavlovich C.P., Folkman J., Voest E.E., Chen X., Luster A.D. Intravesical BCG induces the anti-angiogenic chemokine IP-10. Urology. 52:1998;268-275.
13. Weiss G., O'Donnell M.A., Conlon K., Sherman M. Phase I trial of the intravesical administration of recombinant human interleukin-12 (rhIL-12) for superficial transitional cell bladder carcinoma (STCC). Am Soc Clin Oncol. 18:1999;334a.
14. O'Donnell M.A., Chen X., Dewolf W.C. Maturation of the cytokine immune response to BCG in the bladder: implications for treatment schedules. J Urol. 155:1996;1030A.
15. Riemensberger J., Bohle A., Brandau S. IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin Exp Immunol. 127:2002;20-26.
16. McAveney K.M., Gomella L.G., Lattime E.C. Induction of TH1- and TH2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapy. Cancer Immunol Immunother. 39:1994;401-406.
17. Ratliff T.L., Ritchey J.K., Yuan J.J., Andriole G.L., Catalona W.J. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol. 150:1993;1018-1023.
18. Ratliff T.L. Role of the immune response in BCG for bladder cancer. Eur Urol. 21:(Suppl 2):1992;17-21.
19. Lamm D.L. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am. 19:1992;573-580.
20. Dejager R., Guinan P., Lamm D. Long-term complete remission in bladder carcinoma in situ with intravesical Tice bacillus Calmette-Guérin. Urology. 38:1991;507-513.
21. Herr H.W., Pinsky C.M., Whitmore W.F. Long-term effect of intravesical bacillus Calmette-Guérin on flat carcinoma in situ of the bladder. J Urol. 135:1986;265-267.
22. Steg A., Adjiman S., Debre B. BCG therapy in superficial bladder tumours - complications and precautions. Eur Urol. 21:(Suppl 2):1992;35-40.
23. Lamm D.L., Van Der Meijden ADPM, Morales A., Brosman S.A., Catalona W.J., Herr H.W., et al. Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J Urol. 147:1992;596-600.
24. Naitoh J., Franklin J., O'Donnell M.A., Belldegrun A.S. Interferon alpha for the treatment of superficial bladder cancer. Adv Exp Med Biol. 462:1999;371-386.
25. Luo Y., Chen X., Downs T.M., DeWolf W.C., O'Donnell M.A. IFN-α 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy. J Immunol. 162:1999;2399-2405.
26. Clinton S.K., Canto E., O'Donnell M.A. Interleukin-12: opportunities for the treatment of bladder cancer. Urol Clin North Am. 27:2000;147-155.
27. Bercovich E., Deriu M., Manferrari F., Irianni G. BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder. Arch Ital Urol Androl. 67:1995;257-260.
28. Stricker P., Pryor K., Nicholson T., Goldstein D., Golovsky D., Ferguson R., et al. Bacillus Calmette-Guérin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Urology. 48:1996;957-961.
29. Gomella L.G., McGinnis D.E., Lattime E.C., Butler K., Baltish M., Thompson I., et al. Treatment of transitional cell carcinoma of the bladder with intravesical interleukin-2: a pilot study. Cancer Biother. 8:1993;223-227.
30. Glazier D.B., Bahnson R.R., McLeod D.G., von Roemeling R.W., Messing E.M., Ernstoff M.S. Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer: an eastern cooperative oncology group study. J Urol. 154:1995;66-68.
31. Saint F., Patard J.J., Maille P., Soyeux P., Hoznek A., Salomon L., et al. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. J Urol. 167:2002;364-367.
32. Fujimoto T., O'Donnell M.A., Szilvasi A., Yang H., Duda R.B. Bacillus Calmette-Guérin plus interleukin-2 and/or granulocyte/macrophage-colony-stimulating factor enhances immunocompetent cell production of interferon-γ, which inhibits B16F10 melanoma cell growth in vitro. Cancer Immunol Immunother. 42:1996;280-284.
33. O'Donnell M.A., Luo Y., Chen X., Szilvasi A., Hunter S.E., Clinton S.K. Role of IL-12 in the induction and potentiation of IFN-γ in response to bacillus Calmette-Guérin. J Immunol. 163:1999;4246-4252.
34. + T cells to enhance priming for interferon-γ production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci USA. 90:1993;10188-10192.
35. + T cell subsets and induces early resistance to Leishmania major in mice. J Exp Med. 178:1993;567-577.
36. Chan S.H., Perussia B., Gupta J.W., Kobayashi M.M.P., Young H.A., Wolf S.F., et al. Induction of IFN-γ production by NK cell stimulatory factor (NKSF): characterization of the responder cells and synergy with other inducers. J Exp Med. 173:1991;869-879.
37. Kobayashi M., Fitz L., Ryan M., Hewick R.M., Clark S.C., Chan S., et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med. 170:1989;827-845.
38. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Ann Rev Immunol. 13:1995;251-276.
39. Manetti R., Parronchi P., Giudizi M.G., Piccinni M.P., Maggi E., Trinchieri G., et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med. 177:1993;1199-1204.
40. Fearon D.T., Locksley R.M. The instructive role of innate immunity in the acquired immune response. Science. 27:1996;50-53.
41. Kishimoto T., Akira S., Narazaki M., Taga T. Interleukin-6 family of cytokines and gp130. Blood. 86:1995;1243-1254.
42. Kawano Y., Noma T., Kou K., Yoshizawa I., Yata J. Regulation of human IgG subclass production by cytokines: human IgG subclass production enhanced differentially by interleukin-6. Immunology. 84:1995;278-284.
43. Ramsay A.J., Husband A.J., Ramshaw I.A., Bao S., Matthaei K.I., Koehler G., et al. The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science. 264:1994;561-563.
44. Taga T., Kawanishi Y., Hardy R.R., Hirano T., Kishimoto T. Receptors for B cell stimulatory factor 2. Quantitation, specificity, distribution, and regulation of their expression. J Exp Med. 166:1987;967-981.
45. Stavropoulos N.E., Hastazeris K., Filiadis I., Milailidis I., Ioachim E., Liamis Z., Kalomiris P. Intravesical instillations of interferon gamma in the prophylaxis of high risk superficial bladder cancer. Scand J Urol Nephrol. 36:2000;218-222.
46. Stover C.K., de la Cruz V.F., Fuerst T.R., Burlein J.E., Benson L.A., Bennett L.T., et al. New use of BCG for recombinant vaccines. Nature. 351:1991;456-460.